As U.S. raises concerns over AstraZeneca’s data reporting, drug company says preliminary info was “consistent with the interim analysis,” but full review coming within 2 days. Source
As U.S. raises concerns over AstraZeneca’s data reporting, drug company says preliminary info was “consistent with the interim analysis,” but full review coming within 2 days. Source